Merck shares surge anew on lung cancer advance, while Bristol-Myers stock plummets

Merck & Co. Inc. drew ahead in a fierce rivalry for advanced lung cancer treatments on Monday, releasing late-stage clinical trial results showing that a cancer drug combination using its Keytruda reduced patients’ risk of death by half, a significant improvement.

The pairing of Keytruda and chemotherapy has already been approved for advanced lung cancer in the U.S., but the latest data should serve to support uptake and the drug’s sales. Merck MRK, +2.61% shares rose nearly 3% in heavy Monday trade.

Lung cancer is the most common kind of cancer in the U.S., and smoking is linked with the vast majority of cases.

>>> Original Source <<<